ECSP088113A - Nuevos derivados de pirazina - Google Patents

Nuevos derivados de pirazina

Info

Publication number
ECSP088113A
ECSP088113A EC2008008113A ECSP088113A ECSP088113A EC SP088113 A ECSP088113 A EC SP088113A EC 2008008113 A EC2008008113 A EC 2008008113A EC SP088113 A ECSP088113 A EC SP088113A EC SP088113 A ECSP088113 A EC SP088113A
Authority
EC
Ecuador
Prior art keywords
pirazina
iia
new derivatives
formula
optionally substituted
Prior art date
Application number
EC2008008113A
Other languages
English (en)
Inventor
Juan Bernat Vidal
Trias Cristina Esteve
Pueyo Lidia Soca
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35945119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of ECSP088113A publication Critical patent/ECSP088113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención da a conocer un compuesto de fórmula (I) en el que: A representa un grupo arilo o heteroarilo monocíclico o policíclico opcionalmente sustituido B representa un grupo heteroarilo conteniendo nitrógeno monocíclico opcionalmente sustituido; y a) R1 y R2 representan hidrógeno o sustituyentes especificados, o b) R2 y R1 y el grupo -NH- al que R1 está unido, forman una porción seleccionada de la porción de fórmula (IIa) y (IIb): (IIa) Estos compuestos son útiles como antagonistas del receptor A2B, en el tratamiento del asma.
EC2008008113A 2005-07-29 2008-01-17 Nuevos derivados de pirazina ECSP088113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200501876A ES2270715B1 (es) 2005-07-29 2005-07-29 Nuevos derivados de pirazina.

Publications (1)

Publication Number Publication Date
ECSP088113A true ECSP088113A (es) 2008-02-20

Family

ID=35945119

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008113A ECSP088113A (es) 2005-07-29 2008-01-17 Nuevos derivados de pirazina

Country Status (22)

Country Link
US (2) US7790728B2 (es)
EP (1) EP1922313A1 (es)
JP (1) JP2009502837A (es)
KR (1) KR20080040681A (es)
CN (1) CN101268064A (es)
AR (1) AR056008A1 (es)
AU (1) AU2006278875A1 (es)
CA (1) CA2616428A1 (es)
EC (1) ECSP088113A (es)
ES (1) ES2270715B1 (es)
IL (1) IL188725A0 (es)
MX (1) MX2008001035A (es)
NO (1) NO20080451L (es)
NZ (1) NZ565150A (es)
PE (1) PE20070407A1 (es)
RU (1) RU2417994C2 (es)
SG (1) SG162805A1 (es)
TW (1) TW200728299A (es)
UA (1) UA93883C2 (es)
UY (1) UY29672A1 (es)
WO (1) WO2007017096A1 (es)
ZA (1) ZA200800353B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422376B (zh) 2005-01-25 2014-01-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之化合物
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ATE517107T1 (de) * 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitoren
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
PT2394999E (pt) 2009-02-06 2014-05-02 Nippon Shinyaku Co Ltd Derivado de aminopirazina e medicamento correspondente
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
RU2625791C2 (ru) * 2010-02-05 2017-07-19 Хептейрес Терапьютикс Лимитед Производные 1,2,4-триазин-4-амина
CN101817823B (zh) * 2010-03-31 2012-09-12 上海毕得医药科技有限公司 4，7-二氮杂吲哚及其5位取代物的制备方法
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TWI659030B (zh) * 2011-10-26 2019-05-11 諾華公司 Ｉｐ受體促效劑雜環化合物
US20150005311A1 (en) * 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105065A1 (en) * 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
JP6058698B2 (ja) * 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
US20140378463A1 (en) * 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
WO2013105061A1 (en) * 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014087208A2 (en) * 2012-12-06 2014-06-12 Enaltec Labs Pvt. Ltd. A process of preparing alcaftadine
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CN103364500B (zh) * 2013-06-29 2019-01-22 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定比拉斯汀原料及其制剂的方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10472347B2 (en) * 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
AU2015370911B2 (en) 2014-12-23 2020-07-09 Bergenbio Asa Inhibitors of Akt kinase
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7013213B2 (ja) * 2017-05-26 2022-01-31 日本化薬株式会社 ピラジン化合物
MX2020000693A (es) * 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos de 1,8-naftiridinona, y usos de los mismos.
AU2018302179A1 (en) * 2017-07-18 2020-02-13 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
MX2020011050A (es) 2018-04-20 2021-03-09 Virginia Tech Intellectual Properties Inc Imidazopiridinas útiles como desacopladores mitocondriales.
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
CN109020881B (zh) * 2018-06-28 2020-04-28 新发药业有限公司 一种阿帕替尼的制备方法
CN112279837B (zh) * 2018-08-17 2022-08-09 迪哲(江苏)医药股份有限公司 吡嗪化合物和其用途
JP7510426B2 (ja) * 2018-10-24 2024-07-03 リードエックスプロ アーゲー 官能化されたアミノトリアジン
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
CN111377906B (zh) * 2018-12-28 2022-09-02 四川科伦博泰生物医药股份有限公司 取代的吡嗪化合物及其制备方法和用途
EP3904352A4 (en) * 2018-12-28 2022-09-07 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SUBSTITUTED ARYL COMPOUND, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
AU2020208644A1 (en) * 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
AU2020207952A1 (en) * 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110407677B (zh) * 2019-06-17 2022-10-11 南京先进生物材料与过程装备研究院有限公司 二苯乙二酮类化合物的制备方法及应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112608316B (zh) * 2019-07-30 2022-10-21 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类腺苷受体拮抗剂
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021146629A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2021146631A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN116903634B (zh) * 2023-07-17 2025-07-29 上海美迪西生物医药股份有限公司 一种6-苯基噻吩并[2,3-b]吡嗪的制备方法
WO2025036840A1 (en) * 2023-08-11 2025-02-20 Almirall, S.A. Pyridine or pyrazine derivatives as collagen vii (c7) inducers and their use in therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
JP2000506532A (ja) 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
EP1042293B9 (en) 1997-12-19 2008-09-03 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
NZ516260A (en) 1999-07-02 2004-08-27 Eisai Co Ltd Fused imidazole compounds and remedies for diabetes mellitus
CA2383351C (en) 1999-08-31 2005-11-01 Vanderbilt University Xanthine derivatives as selective antagonists of a2b adenosine receptors
WO2001060350A2 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
KR100521735B1 (ko) 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
IL152023A0 (en) 2000-04-26 2003-04-10 Eisai Co Ltd Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
EP1308441B1 (en) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DK1401837T3 (da) 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
UA84404C2 (ru) 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
AU2003249604B2 (en) 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
DK1658291T3 (da) 2003-08-25 2013-10-28 Dogwood Pharmaceuticals Inc Substituerede 8-heteroaryl xanthiner
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
EP1678160A1 (en) * 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
DE602004018808D1 (de) 2003-10-31 2009-02-12 Cv Therapeutics Inc Antagonisten des a2b-adenosinrezeptors
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
CN101268064A (zh) 2008-09-17
NZ565150A (en) 2011-02-25
CA2616428A1 (en) 2007-02-15
ZA200800353B (en) 2008-12-31
NO20080451L (no) 2008-02-11
AR056008A1 (es) 2007-09-12
US20090042891A1 (en) 2009-02-12
IL188725A0 (en) 2008-08-07
ES2270715B1 (es) 2008-04-01
US20100273757A1 (en) 2010-10-28
ES2270715A1 (es) 2007-04-01
MX2008001035A (es) 2008-03-14
UA93883C2 (ru) 2011-03-25
RU2008107264A (ru) 2009-09-10
AU2006278875A1 (en) 2007-02-15
KR20080040681A (ko) 2008-05-08
TW200728299A (en) 2007-08-01
RU2417994C2 (ru) 2011-05-10
PE20070407A1 (es) 2007-05-12
JP2009502837A (ja) 2009-01-29
WO2007017096A1 (en) 2007-02-15
SG162805A1 (en) 2010-07-29
UY29672A1 (es) 2007-01-31
EP1922313A1 (en) 2008-05-21
US7790728B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
ECSP088113A (es) Nuevos derivados de pirazina
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6321239A2 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
MX344669B (es) Agente antiplaquetas novedoso.
ECSP11010880A (es) Compuestos orgánicos
CU20120100A7 (es) Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
PH12013501489A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
GT200700036A (es) Compuestos fenil amido heterociclicos condensados
PA8843701A1 (es) Derivados de indolina y métodos para usarlos
CY1116343T1 (el) Φολικα, συνθεσεις και χρησεις αυτων
CR11653A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
UA109525C2 (xx) Алкіламідна сполука і її застосування
SV2010003459A (es) Derivados de pirimidina 934
GT200500272A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CO6150181A2 (es) Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
PE20090372A1 (es) Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
DOP2006000234A (es) Inhibidores de cinasa
GT200600217A (es) Proceso para la sintesis de compuestos organicos
CY1107193T1 (el) Παραγωγα πιπεραζινης και η χρηση τους ως αναστολεων της επανασυλληψης της σεροτονινης ή ως ανταγωνιστων της νευροκινινης